Thursday, at a medical conference being hosted by the Michael J. Fox Foundation, a biotechnology company is presenting the first human data from a Parkinson’s drug that several of the world’s largest drug companies nearly abandoned.
The company, Denali Therapeutics, is run by a widely respected team that formerly worked at Genentech, the Roche unit, and it had one of the largest biotech initial public offerings of 2017. But the stock is down 16% from its IPO price.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,